Advanced search
Publication Cover
Leukemia & Lymphoma Volume 47, 2006 - Issue 11
Submit an article Journal homepage
42
Views
5
CrossRef citations to date
0
Altmetric
Letter to the Editor

The efficacy of low dose thalidomide in refractory/relapsed myeloma—a retrospective audit

G. Cherian Department of Haematology, Derriford Hospital, Plymouth, UK
,
D. W. Thomas Department of Haematology, Derriford Hospital, Plymouth, UK
&
Dr. S. A. J. Rule Department of Haematology, Derriford Hospital, Plymouth, UKCorrespondence[email protected]
Pages 2409-2411 | Accepted 22 Jun 2006, Published online: 01 Jul 2009

References

  • Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddleman P, et al. Antitumour activity in thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571
  • Garcia-Sanz R, Gonzalez-Fraile M I, Sierra M, Lopez C, Gonzales M, Miguel J F. The combination of thalidomide, cyclophosphamide and dexamethasone is feasible and can be an option in relapsed/refractory multiple myeloma. Haematol J 2002; 3: 43–48
  • Barlogie B, Tricot G, Anaissie E. Thalidomide in the management of multiple myeloma. Sem Oncol 2001; 28: 577–582
  • Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthon C, et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients. Haematol J 2002; 3: 185–192
  • Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho A D, et al. Dose-dependent effects of thalidomide on overall survival of relapsed multiple myeloma. Clin Cancer Res 2002; 8: 3377–3382
  • Schey S A, Cavenagh J, Johnson R. A UK myeloma forum phase II study of thalidomide; long term follow up and recommendations for treatment. Leuk Res 2003; 27: 909–914
  • Kees M, Dimou G, Sillaber C, Drach J, Ackerman J, Lechner K, et al. Low dose thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2003; 44: 1943–1946
  • Durie G M. Low dose thalidomide in myeloma. Sem Oncol 2002; 29(suppl 17)34–38
  • Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation. Myeloma sub-committee of the EBMT. Br J Haematol 1998; 102: 1115–1123
  • Waage A, Gimsing P, Juliusson G, Turesson I, Gulbrandsen N, Eriksson T, et al. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. Br J Haematol 2004; 125: 149–155
  • Offidani M, Corvatta L, Macroni M, Malebra L, Mele A, Olivieri A, et al. Common and rare side-effects of low dose thalidomide in multiple myeloma: focus on dose-minimizing peripheral neuropathy. Eur J Haematol 2004; 72: 403–409
  • Isoardo G, Bergui M, Durelli L, Barbero P, Bertola A, Ciaramitaro P, et al. Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol Scand Mar 2004; 109: 188–193

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.